#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=1 .
1-1	0-1	1	quantity	new	_	_
1-2	2-3	.	_	_	_	_

#Text=Introduction
2-1	4-16	Introduction	abstract	new	_	_

#Text=Schizophrenia is a severe mental illness that affects about one percent of the world ’s population .
3-1	17-30	Schizophrenia	abstract	new	coref	3-3[4_0]
3-2	31-33	is	_	_	_	_
3-3	34-35	a	abstract[4]	giv[4]	coref	4-4[0_4]
3-4	36-42	severe	abstract[4]	giv[4]	_	_
3-5	43-49	mental	abstract[4]	giv[4]	_	_
3-6	50-57	illness	abstract[4]	giv[4]	_	_
3-7	58-62	that	_	_	_	_
3-8	63-70	affects	_	_	_	_
3-9	71-76	about	person[5]	new[5]	_	_
3-10	77-80	one	person[5]	new[5]	_	_
3-11	81-88	percent	person[5]	new[5]	_	_
3-12	89-91	of	person[5]	new[5]	_	_
3-13	92-95	the	person[5]|abstract[7]	new[5]|new[7]	_	_
3-14	96-101	world	person[5]|place[6]|abstract[7]	new[5]|new[6]|new[7]	_	_
3-15	102-104	’s	person[5]|place[6]|abstract[7]	new[5]|new[6]|new[7]	_	_
3-16	105-115	population	person[5]|abstract[7]	new[5]|new[7]	_	_
3-17	116-117	.	_	_	_	_

#Text=The patients with schizophrenia are characterized with cognitive impairment , confusion , hallucinations and deterioration of social function .
4-1	118-121	The	person[8]	new[8]	coref	5-12[18_8]
4-2	122-130	patients	person[8]	new[8]	_	_
4-3	131-135	with	person[8]	new[8]	_	_
4-4	136-149	schizophrenia	person[8]|abstract	new[8]|giv	coref	5-5
4-5	150-153	are	_	_	_	_
4-6	154-167	characterized	_	_	_	_
4-7	168-172	with	_	_	_	_
4-8	173-182	cognitive	abstract[10]	new[10]	_	_
4-9	183-193	impairment	abstract[10]	new[10]	_	_
4-10	194-195	,	_	_	_	_
4-11	196-205	confusion	abstract	new	_	_
4-12	206-207	,	_	_	_	_
4-13	208-222	hallucinations	abstract	new	_	_
4-14	223-226	and	_	_	_	_
4-15	227-240	deterioration	abstract[13]	new[13]	_	_
4-16	241-243	of	abstract[13]	new[13]	_	_
4-17	244-250	social	abstract[13]|abstract[14]	new[13]|new[14]	ana	5-1[0_14]
4-18	251-259	function	abstract[13]|abstract[14]	new[13]|new[14]	_	_
4-19	260-261	.	_	_	_	_

#Text=It is noted that schizophrenia leads to a heavy burden on the patients , their families and society .
5-1	262-264	It	abstract	giv	_	_
5-2	265-267	is	_	_	_	_
5-3	268-273	noted	_	_	_	_
5-4	274-278	that	_	_	_	_
5-5	279-292	schizophrenia	abstract	giv	coref	6-11
5-6	293-298	leads	_	_	_	_
5-7	299-301	to	_	_	_	_
5-8	302-303	a	abstract[17]	new[17]	_	_
5-9	304-309	heavy	abstract[17]	new[17]	_	_
5-10	310-316	burden	abstract[17]	new[17]	_	_
5-11	317-319	on	abstract[17]	new[17]	_	_
5-12	320-323	the	abstract[17]|person[18]	new[17]|giv[18]	coref	17-38[120_18]
5-13	324-332	patients	abstract[17]|person[18]	new[17]|giv[18]	_	_
5-14	333-334	,	abstract[17]|person[18]	new[17]|giv[18]	_	_
5-15	335-340	their	abstract[17]|person[18]|person[19]	new[17]|giv[18]|new[19]	_	_
5-16	341-349	families	abstract[17]|person[18]|person[19]	new[17]|giv[18]|new[19]	_	_
5-17	350-353	and	abstract[17]|person[18]	new[17]|giv[18]	_	_
5-18	354-361	society	abstract[17]|person[18]|abstract	new[17]|giv[18]|new	_	_
5-19	362-363	.	_	_	_	_

#Text=Substantial efforts have been devoted to elucidating the pathophysiology of schizophrenia development from genetic and environmental perspectives , as well as gene-environment interactions .
6-1	364-375	Substantial	abstract[21]	new[21]	_	_
6-2	376-383	efforts	abstract[21]	new[21]	_	_
6-3	384-388	have	_	_	_	_
6-4	389-393	been	_	_	_	_
6-5	394-401	devoted	_	_	_	_
6-6	402-404	to	_	_	_	_
6-7	405-416	elucidating	_	_	_	_
6-8	417-420	the	abstract[22]	new[22]	_	_
6-9	421-436	pathophysiology	abstract[22]	new[22]	_	_
6-10	437-439	of	abstract[22]	new[22]	_	_
6-11	440-453	schizophrenia	abstract[22]|abstract|abstract[24]	new[22]|giv|new[24]	coref|coref	7-13|7-13
6-12	454-465	development	abstract[22]|abstract[24]	new[22]|new[24]	_	_
6-13	466-470	from	abstract[22]|abstract[24]	new[22]|new[24]	_	_
6-14	471-478	genetic	abstract[22]|abstract[24]|abstract[25]	new[22]|new[24]|new[25]	_	_
6-15	479-482	and	abstract[22]|abstract[24]|abstract[25]	new[22]|new[24]|new[25]	_	_
6-16	483-496	environmental	abstract[22]|abstract[24]|abstract[25]	new[22]|new[24]|new[25]	_	_
6-17	497-509	perspectives	abstract[22]|abstract[24]|abstract[25]	new[22]|new[24]|new[25]	_	_
6-18	510-511	,	_	_	_	_
6-19	512-514	as	_	_	_	_
6-20	515-519	well	_	_	_	_
6-21	520-522	as	_	_	_	_
6-22	523-539	gene-environment	abstract|abstract[27]	new|new[27]	_	_
6-23	540-552	interactions	abstract[27]	new[27]	_	_
6-24	553-554	.	_	_	_	_

#Text=Epidemiological studies have suggested that urban environments could increase the risk of schizophrenia , which may be due to the exposure to the toxic heavy metals ( THMs ) in the environment .
7-1	555-570	Epidemiological	abstract[28]	new[28]	coref	16-2[106_28]
7-2	571-578	studies	abstract[28]	new[28]	_	_
7-3	579-583	have	_	_	_	_
7-4	584-593	suggested	_	_	_	_
7-5	594-598	that	_	_	_	_
7-6	599-604	urban	place[29]	new[29]	_	_
7-7	605-617	environments	place[29]	new[29]	_	_
7-8	618-623	could	_	_	_	_
7-9	624-632	increase	_	_	_	_
7-10	633-636	the	abstract[30]	new[30]	coref	10-7[0_30]
7-11	637-641	risk	abstract[30]	new[30]	_	_
7-12	642-644	of	abstract[30]	new[30]	_	_
7-13	645-658	schizophrenia	abstract[30]|abstract	new[30]|giv	coref	12-20[82_0]
7-14	659-660	,	_	_	_	_
7-15	661-666	which	_	_	_	_
7-16	667-670	may	_	_	_	_
7-17	671-673	be	_	_	_	_
7-18	674-677	due	_	_	_	_
7-19	678-680	to	_	_	_	_
7-20	681-684	the	abstract[32]	new[32]	coref	8-1[36_32]
7-21	685-693	exposure	abstract[32]	new[32]	_	_
7-22	694-696	to	abstract[32]	new[32]	_	_
7-23	697-700	the	abstract[32]|substance[33]	new[32]|new[33]	appos	7-28[0_33]
7-24	701-706	toxic	abstract[32]|substance[33]	new[32]|new[33]	_	_
7-25	707-712	heavy	abstract[32]|substance[33]	new[32]|new[33]	_	_
7-26	713-719	metals	abstract[32]|substance[33]	new[32]|new[33]	_	_
7-27	720-721	(	_	_	_	_
7-28	722-726	THMs	substance	giv	coref	8-4
7-29	727-728	)	_	_	_	_
7-30	729-731	in	_	_	_	_
7-31	732-735	the	place[35]	new[35]	_	_
7-32	736-747	environment	place[35]	new[35]	_	_
7-33	748-749	.	_	_	_	_

#Text=Chronic exposure to THMs impairs numerous biological functions and results in a series of health problems , such as aberrant immunological responses and neuropathological conditions .
8-1	750-757	Chronic	abstract[36]	giv[36]	coref	13-7[88_36]
8-2	758-766	exposure	abstract[36]	giv[36]	_	_
8-3	767-769	to	abstract[36]	giv[36]	_	_
8-4	770-774	THMs	abstract[36]|substance	giv[36]|giv	coref	9-8
8-5	775-782	impairs	_	_	_	_
8-6	783-791	numerous	abstract[38]	new[38]	_	_
8-7	792-802	biological	abstract[38]	new[38]	_	_
8-8	803-812	functions	abstract[38]	new[38]	_	_
8-9	813-816	and	_	_	_	_
8-10	817-824	results	abstract[39]	new[39]	coref	16-13[110_39]
8-11	825-827	in	abstract[39]	new[39]	_	_
8-12	828-829	a	abstract[39]|abstract[40]	new[39]|new[40]	ana	9-3[0_40]
8-13	830-836	series	abstract[39]|abstract[40]	new[39]|new[40]	_	_
8-14	837-839	of	abstract[39]|abstract[40]	new[39]|new[40]	_	_
8-15	840-846	health	abstract[39]|abstract[40]|abstract|abstract[42]	new[39]|new[40]|new|new[42]	_	_
8-16	847-855	problems	abstract[39]|abstract[40]|abstract[42]	new[39]|new[40]|new[42]	_	_
8-17	856-857	,	abstract[39]|abstract[40]	new[39]|new[40]	_	_
8-18	858-862	such	abstract[39]|abstract[40]	new[39]|new[40]	_	_
8-19	863-865	as	abstract[39]|abstract[40]	new[39]|new[40]	_	_
8-20	866-874	aberrant	abstract[39]|abstract[40]|abstract[43]	new[39]|new[40]|new[43]	_	_
8-21	875-888	immunological	abstract[39]|abstract[40]|abstract[43]	new[39]|new[40]|new[43]	_	_
8-22	889-898	responses	abstract[39]|abstract[40]|abstract[43]	new[39]|new[40]|new[43]	_	_
8-23	899-902	and	abstract[39]|abstract[40]	new[39]|new[40]	_	_
8-24	903-920	neuropathological	abstract[39]|abstract[40]|abstract[44]	new[39]|new[40]|new[44]	_	_
8-25	921-931	conditions	abstract[39]|abstract[40]|abstract[44]	new[39]|new[40]|new[44]	_	_
8-26	932-933	.	_	_	_	_

#Text=Moreover , it has been reported that THMs could cause oxidative stress and subsequently DNA damage , lipid peroxidation and protein modification , which play a role in the pathogenesis of numerous diseases , including cancer , diabetes , neurological disorders and chronic inflammation .
9-1	934-942	Moreover	_	_	_	_
9-2	943-944	,	_	_	_	_
9-3	945-947	it	abstract	giv	_	_
9-4	948-951	has	_	_	_	_
9-5	952-956	been	_	_	_	_
9-6	957-965	reported	_	_	_	_
9-7	966-970	that	_	_	_	_
9-8	971-975	THMs	substance	giv	coref	10-1
9-9	976-981	could	_	_	_	_
9-10	982-987	cause	_	_	_	_
9-11	988-997	oxidative	abstract|abstract[48]	new|new[48]	_	_
9-12	998-1004	stress	abstract[48]	new[48]	_	_
9-13	1005-1008	and	_	_	_	_
9-14	1009-1021	subsequently	abstract[50]	new[50]	_	_
9-15	1022-1025	DNA	substance|abstract[50]	new|new[50]	_	_
9-16	1026-1032	damage	abstract[50]	new[50]	_	_
9-17	1033-1034	,	_	_	_	_
9-18	1035-1040	lipid	person|substance[52]	new|new[52]	_	_
9-19	1041-1053	peroxidation	substance[52]	new[52]	_	_
9-20	1054-1057	and	_	_	_	_
9-21	1058-1065	protein	substance|abstract[54]	new|new[54]	coref|coref	11-20[73_0]|11-20[73_0]
9-22	1066-1078	modification	abstract[54]	new[54]	_	_
9-23	1079-1080	,	_	_	_	_
9-24	1081-1086	which	_	_	_	_
9-25	1087-1091	play	_	_	_	_
9-26	1092-1093	a	abstract[55]	new[55]	coref	25-22[185_55]
9-27	1094-1098	role	abstract[55]	new[55]	_	_
9-28	1099-1101	in	abstract[55]	new[55]	_	_
9-29	1102-1105	the	abstract[55]|abstract[56]	new[55]|new[56]	_	_
9-30	1106-1118	pathogenesis	abstract[55]|abstract[56]	new[55]|new[56]	_	_
9-31	1119-1121	of	abstract[55]|abstract[56]	new[55]|new[56]	_	_
9-32	1122-1130	numerous	abstract[55]|abstract[56]|abstract[57]	new[55]|new[56]|new[57]	coref	10-10[64_57]
9-33	1131-1139	diseases	abstract[55]|abstract[56]|abstract[57]	new[55]|new[56]|new[57]	_	_
9-34	1140-1141	,	abstract[55]|abstract[56]|abstract[57]	new[55]|new[56]|new[57]	_	_
9-35	1142-1151	including	abstract[55]|abstract[56]|abstract[57]	new[55]|new[56]|new[57]	_	_
9-36	1152-1158	cancer	abstract[55]|abstract[56]|abstract[57]|event	new[55]|new[56]|new[57]|new	_	_
9-37	1159-1160	,	abstract[55]|abstract[56]|abstract[57]	new[55]|new[56]|new[57]	_	_
9-38	1161-1169	diabetes	abstract[55]|abstract[56]|abstract[57]|abstract	new[55]|new[56]|new[57]|new	_	_
9-39	1170-1171	,	abstract[55]|abstract[56]|abstract[57]	new[55]|new[56]|new[57]	_	_
9-40	1172-1184	neurological	abstract[55]|abstract[56]|abstract[57]|abstract[60]	new[55]|new[56]|new[57]|new[60]	_	_
9-41	1185-1194	disorders	abstract[55]|abstract[56]|abstract[57]|abstract[60]	new[55]|new[56]|new[57]|new[60]	_	_
9-42	1195-1198	and	abstract[55]|abstract[56]|abstract[57]	new[55]|new[56]|new[57]	_	_
9-43	1199-1206	chronic	abstract[55]|abstract[56]|abstract[57]|abstract[61]	new[55]|new[56]|new[57]|new[61]	_	_
9-44	1207-1219	inflammation	abstract[55]|abstract[56]|abstract[57]|abstract[61]	new[55]|new[56]|new[57]|new[61]	_	_
9-45	1220-1221	.	_	_	_	_

#Text=THMs are suggested as an important risk factor for mental diseases since they cause neurobehavioral alterations and disrupt dopamine receptors .
10-1	1222-1226	THMs	abstract	giv	coref	14-5
10-2	1227-1230	are	_	_	_	_
10-3	1231-1240	suggested	_	_	_	_
10-4	1241-1243	as	_	_	_	_
10-5	1244-1246	an	_	_	_	_
10-6	1247-1256	important	_	_	_	_
10-7	1257-1261	risk	abstract	giv	coref	15-15[104_0]
10-8	1262-1268	factor	_	_	_	_
10-9	1269-1272	for	_	_	_	_
10-10	1273-1279	mental	abstract[64]	giv[64]	ana	10-13[0_64]
10-11	1280-1288	diseases	abstract[64]	giv[64]	_	_
10-12	1289-1294	since	_	_	_	_
10-13	1295-1299	they	abstract	giv	coref	11-34[76_0]
10-14	1300-1305	cause	_	_	_	_
10-15	1306-1321	neurobehavioral	abstract[66]	new[66]	_	_
10-16	1322-1333	alterations	abstract[66]	new[66]	_	_
10-17	1334-1337	and	_	_	_	_
10-18	1338-1345	disrupt	_	_	_	_
10-19	1346-1354	dopamine	abstract|object[68]	new|new[68]	_	_
10-20	1355-1364	receptors	object[68]	new[68]	_	_
10-21	1365-1366	.	_	_	_	_

#Text=For example , arsenic ( As ) -induced neurotoxicity has been reported to cause compositional changes and hyperphosphorylation on the cytoskeletal protein , leading to the disintegration of the cytoskeletal framework and causing neurodegenerative diseases .
11-1	1367-1370	For	_	_	_	_
11-2	1371-1378	example	_	_	_	_
11-3	1379-1380	,	_	_	_	_
11-4	1381-1388	arsenic	substance	new	_	_
11-5	1389-1390	(	_	_	_	_
11-6	1391-1393	As	_	_	_	_
11-7	1394-1395	)	_	_	_	_
11-8	1396-1404	-induced	_	_	_	_
11-9	1405-1418	neurotoxicity	abstract	new	_	_
11-10	1419-1422	has	_	_	_	_
11-11	1423-1427	been	_	_	_	_
11-12	1428-1436	reported	_	_	_	_
11-13	1437-1439	to	_	_	_	_
11-14	1440-1445	cause	_	_	_	_
11-15	1446-1459	compositional	abstract[71]	new[71]	coref	15-1[100_71]
11-16	1460-1467	changes	abstract[71]	new[71]	_	_
11-17	1468-1471	and	_	_	_	_
11-18	1472-1492	hyperphosphorylation	abstract[72]	new[72]	_	_
11-19	1493-1495	on	abstract[72]	new[72]	_	_
11-20	1496-1499	the	abstract[72]|substance[73]	new[72]|giv[73]	_	_
11-21	1500-1512	cytoskeletal	abstract[72]|substance[73]	new[72]|giv[73]	_	_
11-22	1513-1520	protein	abstract[72]|substance[73]	new[72]|giv[73]	_	_
11-23	1521-1522	,	_	_	_	_
11-24	1523-1530	leading	_	_	_	_
11-25	1531-1533	to	_	_	_	_
11-26	1534-1537	the	abstract[74]	new[74]	_	_
11-27	1538-1552	disintegration	abstract[74]	new[74]	_	_
11-28	1553-1555	of	abstract[74]	new[74]	_	_
11-29	1556-1559	the	abstract[74]|object[75]	new[74]|new[75]	_	_
11-30	1560-1572	cytoskeletal	abstract[74]|object[75]	new[74]|new[75]	_	_
11-31	1573-1582	framework	abstract[74]|object[75]	new[74]|new[75]	_	_
11-32	1583-1586	and	_	_	_	_
11-33	1587-1594	causing	_	_	_	_
11-34	1595-1612	neurodegenerative	abstract[76]	giv[76]	coref	25-18[184_76]
11-35	1613-1621	diseases	abstract[76]	giv[76]	_	_
11-36	1622-1623	.	_	_	_	_

#Text=An animal study showed lead ( Pb ) as an environmental toxin , which contributed to the pathogenesis of schizophrenia in Disrupted-in-Schizophrenia 1 ( Disc1)-mutant mice .
12-1	1624-1626	An	abstract[78]	new[78]	coref	13-16[91_78]
12-2	1627-1633	animal	person|abstract[78]	new|new[78]	_	_
12-3	1634-1639	study	abstract[78]	new[78]	_	_
12-4	1640-1646	showed	_	_	_	_
12-5	1647-1651	lead	substance	new	appos	12-7
12-6	1652-1653	(	_	_	_	_
12-7	1654-1656	Pb	substance	giv	coref	17-17
12-8	1657-1658	)	_	_	_	_
12-9	1659-1661	as	_	_	_	_
12-10	1662-1664	an	_	_	_	_
12-11	1665-1678	environmental	_	_	_	_
12-12	1679-1684	toxin	_	_	_	_
12-13	1685-1686	,	_	_	_	_
12-14	1687-1692	which	_	_	_	_
12-15	1693-1704	contributed	_	_	_	_
12-16	1705-1707	to	_	_	_	_
12-17	1708-1711	the	abstract[81]	new[81]	_	_
12-18	1712-1724	pathogenesis	abstract[81]	new[81]	_	_
12-19	1725-1727	of	abstract[81]	new[81]	_	_
12-20	1728-1741	schizophrenia	abstract[81]|abstract[82]	new[81]|giv[82]	coref	13-14[90_82]
12-21	1742-1744	in	abstract[81]|abstract[82]	new[81]|giv[82]	_	_
12-22	1745-1771	Disrupted-in-Schizophrenia	abstract[81]|abstract[82]|abstract[83]	new[81]|giv[82]|new[83]	_	_
12-23	1772-1773	1	abstract[81]|abstract[82]|abstract[83]	new[81]|giv[82]|new[83]	_	_
12-24	1774-1775	(	_	_	_	_
12-25	1776-1789	Disc1)-mutant	animal|animal[85]	new|new[85]	ana|ana	14-16[0_85]|14-16[0_85]
12-26	1790-1794	mice	animal[85]	new[85]	_	_
12-27	1795-1796	.	_	_	_	_

#Text=Therefore , investigating the association of environmental THM exposure with the risk of schizophrenia via a reliable epidemiological study is worthwhile .
13-1	1797-1806	Therefore	_	_	_	_
13-2	1807-1808	,	_	_	_	_
13-3	1809-1822	investigating	_	_	_	_
13-4	1823-1826	the	abstract[86]	new[86]	coref	16-6[107_86]
13-5	1827-1838	association	abstract[86]	new[86]	_	_
13-6	1839-1841	of	abstract[86]	new[86]	_	_
13-7	1842-1855	environmental	abstract[86]|abstract[88]	new[86]|giv[88]	coref	14-21[0_88]
13-8	1856-1859	THM	abstract[86]|substance|abstract[88]	new[86]|new|giv[88]	coref	15-3
13-9	1860-1868	exposure	abstract[86]|abstract[88]	new[86]|giv[88]	_	_
13-10	1869-1873	with	_	_	_	_
13-11	1874-1877	the	abstract[89]	new[89]	_	_
13-12	1878-1882	risk	abstract[89]	new[89]	_	_
13-13	1883-1885	of	abstract[89]	new[89]	_	_
13-14	1886-1899	schizophrenia	abstract[89]|abstract[90]	new[89]|giv[90]	coref	15-18[0_90]
13-15	1900-1903	via	abstract[89]|abstract[90]	new[89]|giv[90]	_	_
13-16	1904-1905	a	abstract[89]|abstract[90]|abstract[91]	new[89]|giv[90]|giv[91]	coref	17-21[115_91]
13-17	1906-1914	reliable	abstract[89]|abstract[90]|abstract[91]	new[89]|giv[90]|giv[91]	_	_
13-18	1915-1930	epidemiological	abstract[89]|abstract[90]|abstract[91]	new[89]|giv[90]|giv[91]	_	_
13-19	1931-1936	study	abstract[89]|abstract[90]|abstract[91]	new[89]|giv[90]|giv[91]	_	_
13-20	1937-1939	is	_	_	_	_
13-21	1940-1950	worthwhile	_	_	_	_
13-22	1951-1952	.	_	_	_	_

#Text=The serum concentration of THMs has been suggested to act as an internal indicator of their intake levels , reflecting exposure to environmental THMs .
14-1	1953-1956	The	quantity[93]	new[93]	_	_
14-2	1957-1962	serum	abstract|quantity[93]	new|new[93]	coref	20-6
14-3	1963-1976	concentration	quantity[93]	new[93]	_	_
14-4	1977-1979	of	quantity[93]	new[93]	_	_
14-5	1980-1984	THMs	quantity[93]|substance	new[93]|giv	coref	14-23[99_0]
14-6	1985-1988	has	_	_	_	_
14-7	1989-1993	been	_	_	_	_
14-8	1994-2003	suggested	_	_	_	_
14-9	2004-2006	to	_	_	_	_
14-10	2007-2010	act	_	_	_	_
14-11	2011-2013	as	_	_	_	_
14-12	2014-2016	an	_	_	_	_
14-13	2017-2025	internal	_	_	_	_
14-14	2026-2035	indicator	_	_	_	_
14-15	2036-2038	of	_	_	_	_
14-16	2039-2044	their	animal|abstract[97]	giv|new[97]	_	_
14-17	2045-2051	intake	event|abstract[97]	new|new[97]	_	_
14-18	2052-2058	levels	abstract[97]	new[97]	_	_
14-19	2059-2060	,	_	_	_	_
14-20	2061-2071	reflecting	_	_	_	_
14-21	2072-2080	exposure	abstract	giv	_	_
14-22	2081-2083	to	_	_	_	_
14-23	2084-2097	environmental	substance[99]	giv[99]	coref	16-9[108_99]
14-24	2098-2102	THMs	substance[99]	giv[99]	_	_
14-25	2103-2104	.	_	_	_	_

#Text=Changes in THM concentrations have been observed in peripheral tissues to be correlated with the risk of schizophrenia .
15-1	2105-2112	Changes	abstract[100]	giv[100]	_	_
15-2	2113-2115	in	abstract[100]	giv[100]	_	_
15-3	2116-2119	THM	abstract[100]|substance|abstract[102]	giv[100]|giv|new[102]	coref|coref	26-22[197_102]|26-22[197_102]
15-4	2120-2134	concentrations	abstract[100]|abstract[102]	giv[100]|new[102]	_	_
15-5	2135-2139	have	_	_	_	_
15-6	2140-2144	been	_	_	_	_
15-7	2145-2153	observed	_	_	_	_
15-8	2154-2156	in	_	_	_	_
15-9	2157-2167	peripheral	object[103]	new[103]	_	_
15-10	2168-2175	tissues	object[103]	new[103]	_	_
15-11	2176-2178	to	_	_	_	_
15-12	2179-2181	be	_	_	_	_
15-13	2182-2192	correlated	_	_	_	_
15-14	2193-2197	with	_	_	_	_
15-15	2198-2201	the	abstract[104]	giv[104]	coref	24-9[0_104]
15-16	2202-2206	risk	abstract[104]	giv[104]	_	_
15-17	2207-2209	of	abstract[104]	giv[104]	_	_
15-18	2210-2223	schizophrenia	abstract[104]|abstract	giv[104]|giv	coref	16-11
15-19	2224-2225	.	_	_	_	_

#Text=Although multiple studies have investigated the association between THMs and schizophrenia , the results remain inconsistent .
16-1	2226-2234	Although	_	_	_	_
16-2	2235-2243	multiple	abstract[106]	giv[106]	coref	23-2[161_106]
16-3	2244-2251	studies	abstract[106]	giv[106]	_	_
16-4	2252-2256	have	_	_	_	_
16-5	2257-2269	investigated	_	_	_	_
16-6	2270-2273	the	abstract[107]	giv[107]	coref	17-14[112_107]
16-7	2274-2285	association	abstract[107]	giv[107]	_	_
16-8	2286-2293	between	abstract[107]	giv[107]	_	_
16-9	2294-2298	THMs	abstract[107]|substance[108]	giv[107]|giv[108]	coref	23-9[163_108]
16-10	2299-2302	and	abstract[107]|substance[108]	giv[107]|giv[108]	_	_
16-11	2303-2316	schizophrenia	abstract[107]|substance[108]|abstract	giv[107]|giv[108]|giv	coref	17-19
16-12	2317-2318	,	_	_	_	_
16-13	2319-2322	the	abstract[110]	giv[110]	_	_
16-14	2323-2330	results	abstract[110]	giv[110]	_	_
16-15	2331-2337	remain	_	_	_	_
16-16	2338-2350	inconsistent	_	_	_	_
16-17	2351-2352	.	_	_	_	_

#Text=For example , despite supporting evidence both in vitro and in vivo for the association between Pb and schizophrenia , a cross-sectional study among a Chinese population showed no significant difference in the concentration of Pb between patients with schizophrenia and healthy controls .
17-1	2353-2356	For	_	_	_	_
17-2	2357-2364	example	_	_	_	_
17-3	2365-2366	,	_	_	_	_
17-4	2367-2374	despite	_	_	_	_
17-5	2375-2385	supporting	_	_	_	_
17-6	2386-2394	evidence	abstract	new	_	_
17-7	2395-2399	both	_	_	_	_
17-8	2400-2402	in	_	_	_	_
17-9	2403-2408	vitro	_	_	_	_
17-10	2409-2412	and	_	_	_	_
17-11	2413-2415	in	_	_	_	_
17-12	2416-2420	vivo	_	_	_	_
17-13	2421-2424	for	_	_	_	_
17-14	2425-2428	the	abstract[112]	giv[112]	coref	18-18[128_112]
17-15	2429-2440	association	abstract[112]	giv[112]	_	_
17-16	2441-2448	between	abstract[112]	giv[112]	_	_
17-17	2449-2451	Pb	abstract[112]|substance	giv[112]|giv	coref	17-36
17-18	2452-2455	and	abstract[112]	giv[112]	_	_
17-19	2456-2469	schizophrenia	abstract[112]|abstract	giv[112]|giv	coref	17-40
17-20	2470-2471	,	_	_	_	_
17-21	2472-2473	a	abstract[115]	giv[115]	coref	18-3[123_115]
17-22	2474-2489	cross-sectional	abstract[115]	giv[115]	_	_
17-23	2490-2495	study	abstract[115]	giv[115]	_	_
17-24	2496-2501	among	abstract[115]	giv[115]	_	_
17-25	2502-2503	a	abstract[115]|person[116]	giv[115]|new[116]	coref	19-13[132_116]
17-26	2504-2511	Chinese	abstract[115]|person[116]	giv[115]|new[116]	_	_
17-27	2512-2522	population	abstract[115]|person[116]	giv[115]|new[116]	_	_
17-28	2523-2529	showed	_	_	_	_
17-29	2530-2532	no	abstract[117]	new[117]	_	_
17-30	2533-2544	significant	abstract[117]	new[117]	_	_
17-31	2545-2555	difference	abstract[117]	new[117]	_	_
17-32	2556-2558	in	abstract[117]	new[117]	_	_
17-33	2559-2562	the	abstract[117]|quantity[118]	new[117]|new[118]	coref	20-11[142_118]
17-34	2563-2576	concentration	abstract[117]|quantity[118]	new[117]|new[118]	_	_
17-35	2577-2579	of	abstract[117]|quantity[118]	new[117]|new[118]	_	_
17-36	2580-2582	Pb	abstract[117]|quantity[118]|substance	new[117]|new[118]|giv	coref	25-11
17-37	2583-2590	between	abstract[117]|quantity[118]	new[117]|new[118]	_	_
17-38	2591-2599	patients	abstract[117]|quantity[118]|person[120]	new[117]|new[118]|giv[120]	coref	19-19[133_120]
17-39	2600-2604	with	abstract[117]|quantity[118]|person[120]	new[117]|new[118]|giv[120]	_	_
17-40	2605-2618	schizophrenia	abstract[117]|quantity[118]|person[120]|abstract	new[117]|new[118]|giv[120]|giv	coref	20-16
17-41	2619-2622	and	abstract[117]|quantity[118]|person[120]	new[117]|new[118]|giv[120]	_	_
17-42	2623-2630	healthy	abstract[117]|quantity[118]|person[120]|person[122]	new[117]|new[118]|giv[120]|new[122]	coref	20-13[143_122]
17-43	2631-2639	controls	abstract[117]|quantity[118]|person[120]|person[122]	new[117]|new[118]|giv[120]|new[122]	_	_
17-44	2640-2641	.	_	_	_	_

#Text=However , another study applying a very similar study design towards the same sampling region resulted in a significant association .
18-1	2642-2649	However	_	_	_	_
18-2	2650-2651	,	_	_	_	_
18-3	2652-2659	another	abstract[123]	giv[123]	coref	18-9[0_123]
18-4	2660-2665	study	abstract[123]	giv[123]	_	_
18-5	2666-2674	applying	_	_	_	_
18-6	2675-2676	a	abstract[125]	new[125]	_	_
18-7	2677-2681	very	abstract[125]	new[125]	_	_
18-8	2682-2689	similar	abstract[125]	new[125]	_	_
18-9	2690-2695	study	abstract|abstract[125]	giv|new[125]	coref	19-30
18-10	2696-2702	design	abstract[125]	new[125]	_	_
18-11	2703-2710	towards	abstract[125]	new[125]	_	_
18-12	2711-2714	the	abstract[125]|place[127]	new[125]|new[127]	_	_
18-13	2715-2719	same	abstract[125]|place[127]	new[125]|new[127]	_	_
18-14	2720-2728	sampling	abstract[125]|person|place[127]	new[125]|new|new[127]	_	_
18-15	2729-2735	region	abstract[125]|place[127]	new[125]|new[127]	_	_
18-16	2736-2744	resulted	_	_	_	_
18-17	2745-2747	in	_	_	_	_
18-18	2748-2749	a	abstract[128]	giv[128]	coref	23-6[162_128]
18-19	2750-2761	significant	abstract[128]	giv[128]	_	_
18-20	2762-2773	association	abstract[128]	giv[128]	_	_
18-21	2774-2775	.	_	_	_	_

#Text=The reason for the divergence may be related to the choice of the population , such as whether the schizophrenic patients have received antipsychotics drug during the time of study .
19-1	2776-2779	The	abstract[129]	new[129]	_	_
19-2	2780-2786	reason	abstract[129]	new[129]	_	_
19-3	2787-2790	for	abstract[129]	new[129]	_	_
19-4	2791-2794	the	abstract[129]|abstract[130]	new[129]|new[130]	_	_
19-5	2795-2805	divergence	abstract[129]|abstract[130]	new[129]|new[130]	_	_
19-6	2806-2809	may	_	_	_	_
19-7	2810-2812	be	_	_	_	_
19-8	2813-2820	related	_	_	_	_
19-9	2821-2823	to	_	_	_	_
19-10	2824-2827	the	abstract[131]	new[131]	_	_
19-11	2828-2834	choice	abstract[131]	new[131]	_	_
19-12	2835-2837	of	abstract[131]	new[131]	_	_
19-13	2838-2841	the	abstract[131]|person[132]	new[131]|giv[132]	_	_
19-14	2842-2852	population	abstract[131]|person[132]	new[131]|giv[132]	_	_
19-15	2853-2854	,	_	_	_	_
19-16	2855-2859	such	_	_	_	_
19-17	2860-2862	as	_	_	_	_
19-18	2863-2870	whether	_	_	_	_
19-19	2871-2874	the	person[133]	giv[133]	coref	20-16[145_133]
19-20	2875-2888	schizophrenic	person[133]	giv[133]	_	_
19-21	2889-2897	patients	person[133]	giv[133]	_	_
19-22	2898-2902	have	_	_	_	_
19-23	2903-2911	received	_	_	_	_
19-24	2912-2926	antipsychotics	abstract|substance[135]	new|new[135]	_	_
19-25	2927-2931	drug	substance[135]	new[135]	_	_
19-26	2932-2938	during	_	_	_	_
19-27	2939-2942	the	time[136]	new[136]	_	_
19-28	2943-2947	time	time[136]	new[136]	_	_
19-29	2948-2950	of	time[136]	new[136]	_	_
19-30	2951-2956	study	time[136]|abstract	new[136]|giv	coref	20-1[138_0]
19-31	2957-2958	.	_	_	_	_

#Text=A previous study has compared serum cadmium ( Cd ) concentration between healthy controls and schizophrenia patients with or without treatment .
20-1	2959-2960	A	abstract[138]	giv[138]	coref	26-5[190_138]
20-2	2961-2969	previous	abstract[138]	giv[138]	_	_
20-3	2970-2975	study	abstract[138]	giv[138]	_	_
20-4	2976-2979	has	_	_	_	_
20-5	2980-2988	compared	_	_	_	_
20-6	2989-2994	serum	abstract|substance[140]	giv|new[140]	appos|coref|appos|coref	20-9[0_140]|21-2|20-9[0_140]|21-2
20-7	2995-3002	cadmium	substance[140]	new[140]	_	_
20-8	3003-3004	(	_	_	_	_
20-9	3005-3007	Cd	substance	giv	coref	21-5[149_0]
20-10	3008-3009	)	_	_	_	_
20-11	3010-3023	concentration	quantity[142]	giv[142]	_	_
20-12	3024-3031	between	quantity[142]	giv[142]	_	_
20-13	3032-3039	healthy	quantity[142]|person[143]	giv[142]|giv[143]	coref	21-16[152_143]
20-14	3040-3048	controls	quantity[142]|person[143]	giv[142]|giv[143]	_	_
20-15	3049-3052	and	quantity[142]|person[143]	giv[142]|giv[143]	_	_
20-16	3053-3066	schizophrenia	quantity[142]|person[143]|abstract|person[145]	giv[142]|giv[143]|giv|giv[145]	coref|coref|coref|coref	21-7[0_145]|22-19|21-7[0_145]|22-19
20-17	3067-3075	patients	quantity[142]|person[143]|person[145]	giv[142]|giv[143]|giv[145]	_	_
20-18	3076-3080	with	_	_	_	_
20-19	3081-3083	or	_	_	_	_
20-20	3084-3091	without	_	_	_	_
20-21	3092-3101	treatment	abstract	new	coref	21-9
20-22	3102-3103	.	_	_	_	_

#Text=The serum concentration of Cd in patients after treatment was significantly higher than that of the healthy controls but no significant change was observed from the pre-treatment patients .
21-1	3104-3107	The	quantity[148]	new[148]	_	_
21-2	3108-3113	serum	abstract|quantity[148]	giv|new[148]	coref	26-22
21-3	3114-3127	concentration	quantity[148]	new[148]	_	_
21-4	3128-3130	of	quantity[148]	new[148]	_	_
21-5	3131-3133	Cd	quantity[148]|substance[149]	new[148]|giv[149]	_	_
21-6	3134-3136	in	quantity[148]|substance[149]	new[148]|giv[149]	_	_
21-7	3137-3145	patients	quantity[148]|substance[149]|person	new[148]|giv[149]|giv	coref	21-26[154_0]
21-8	3146-3151	after	_	_	_	_
21-9	3152-3161	treatment	event	giv	_	_
21-10	3162-3165	was	_	_	_	_
21-11	3166-3179	significantly	_	_	_	_
21-12	3180-3186	higher	_	_	_	_
21-13	3187-3191	than	_	_	_	_
21-14	3192-3196	that	_	_	_	_
21-15	3197-3199	of	_	_	_	_
21-16	3200-3203	the	person[152]	giv[152]	coref	26-15[194_152]
21-17	3204-3211	healthy	person[152]	giv[152]	_	_
21-18	3212-3220	controls	person[152]	giv[152]	_	_
21-19	3221-3224	but	_	_	_	_
21-20	3225-3227	no	abstract[153]	new[153]	_	_
21-21	3228-3239	significant	abstract[153]	new[153]	_	_
21-22	3240-3246	change	abstract[153]	new[153]	_	_
21-23	3247-3250	was	_	_	_	_
21-24	3251-3259	observed	_	_	_	_
21-25	3260-3264	from	_	_	_	_
21-26	3265-3268	the	person[154]	giv[154]	coref	22-13[159_154]
21-27	3269-3282	pre-treatment	person[154]	giv[154]	_	_
21-28	3283-3291	patients	person[154]	giv[154]	_	_
21-29	3292-3293	.	_	_	_	_

#Text=The concentration of antimony and uranium were also found significantly different between pre-treatment patients and post-treatment patients of schizophrenia .
22-1	3294-3297	The	abstract[155]	new[155]	_	_
22-2	3298-3311	concentration	abstract[155]	new[155]	_	_
22-3	3312-3314	of	abstract[155]	new[155]	_	_
22-4	3315-3323	antimony	abstract[155]|substance	new[155]|new	_	_
22-5	3324-3327	and	abstract[155]	new[155]	_	_
22-6	3328-3335	uranium	abstract[155]|substance	new[155]|new	_	_
22-7	3336-3340	were	_	_	_	_
22-8	3341-3345	also	_	_	_	_
22-9	3346-3351	found	_	_	_	_
22-10	3352-3365	significantly	_	_	_	_
22-11	3366-3375	different	_	_	_	_
22-12	3376-3383	between	_	_	_	_
22-13	3384-3397	pre-treatment	event|person[159]	new|giv[159]	coref|coref	24-26[178_159]|24-26[178_159]
22-14	3398-3406	patients	person[159]	giv[159]	_	_
22-15	3407-3410	and	person[159]	giv[159]	_	_
22-16	3411-3425	post-treatment	person[159]	giv[159]	_	_
22-17	3426-3434	patients	person[159]	giv[159]	_	_
22-18	3435-3437	of	person[159]	giv[159]	_	_
22-19	3438-3451	schizophrenia	person[159]|abstract	giv[159]|giv	coref	23-11
22-20	3452-3453	.	_	_	_	_

#Text=Although several studies have investigated the association between THMs and schizophrenia , the potential mechanisms which could link THMs and schizophrenia have not been elucidated .
23-1	3454-3462	Although	_	_	_	_
23-2	3463-3470	several	abstract[161]	giv[161]	coref	24-1[168_161]
23-3	3471-3478	studies	abstract[161]	giv[161]	_	_
23-4	3479-3483	have	_	_	_	_
23-5	3484-3496	investigated	_	_	_	_
23-6	3497-3500	the	abstract[162]	giv[162]	coref	26-19[195_162]
23-7	3501-3512	association	abstract[162]	giv[162]	_	_
23-8	3513-3520	between	abstract[162]	giv[162]	_	_
23-9	3521-3525	THMs	abstract[162]|abstract[163]	giv[162]|giv[163]	coref	23-19[166_163]
23-10	3526-3529	and	abstract[162]|abstract[163]	giv[162]|giv[163]	_	_
23-11	3530-3543	schizophrenia	abstract[162]|abstract[163]|abstract	giv[162]|giv[163]|giv	coref	23-21
23-12	3544-3545	,	_	_	_	_
23-13	3546-3549	the	abstract[165]	new[165]	_	_
23-14	3550-3559	potential	abstract[165]	new[165]	_	_
23-15	3560-3570	mechanisms	abstract[165]	new[165]	_	_
23-16	3571-3576	which	_	_	_	_
23-17	3577-3582	could	_	_	_	_
23-18	3583-3587	link	_	_	_	_
23-19	3588-3592	THMs	abstract[166]	giv[166]	coref	25-6[0_166]
23-20	3593-3596	and	abstract[166]	giv[166]	_	_
23-21	3597-3610	schizophrenia	abstract[166]|abstract	giv[166]|giv	coref	24-12
23-22	3611-3615	have	_	_	_	_
23-23	3616-3619	not	_	_	_	_
23-24	3620-3624	been	_	_	_	_
23-25	3625-3635	elucidated	_	_	_	_
23-26	3636-3637	.	_	_	_	_

#Text=Recent studies have suggested metabolic syndrome as a risk factor of schizophrenia , attributed to poor dietary habits , unhealthy lifestyle and physical inactivity of the patients and side-effects of the second generation-antipsychotics .
24-1	3638-3644	Recent	abstract[168]	giv[168]	coref	26-47[203_168]
24-2	3645-3652	studies	abstract[168]	giv[168]	_	_
24-3	3653-3657	have	_	_	_	_
24-4	3658-3667	suggested	_	_	_	_
24-5	3668-3677	metabolic	person|abstract[170]	new|new[170]	coref|coref	25-18|25-18
24-6	3678-3686	syndrome	abstract[170]	new[170]	_	_
24-7	3687-3689	as	abstract[170]	new[170]	_	_
24-8	3690-3691	a	abstract[170]	new[170]	_	_
24-9	3692-3696	risk	abstract[170]|abstract	new[170]|giv	coref	26-51[204_0]
24-10	3697-3703	factor	abstract[170]	new[170]	_	_
24-11	3704-3706	of	abstract[170]	new[170]	_	_
24-12	3707-3720	schizophrenia	abstract[170]|abstract	new[170]|giv	coref	25-31
24-13	3721-3722	,	_	_	_	_
24-14	3723-3733	attributed	_	_	_	_
24-15	3734-3736	to	_	_	_	_
24-16	3737-3741	poor	abstract[174]	new[174]	_	_
24-17	3742-3749	dietary	abstract|abstract[174]	new|new[174]	_	_
24-18	3750-3756	habits	abstract[174]	new[174]	_	_
24-19	3757-3758	,	_	_	_	_
24-20	3759-3768	unhealthy	abstract[175]	new[175]	_	_
24-21	3769-3778	lifestyle	abstract[175]	new[175]	_	_
24-22	3779-3782	and	_	_	_	_
24-23	3783-3791	physical	abstract[176]	new[176]	_	_
24-24	3792-3802	inactivity	abstract[176]	new[176]	_	_
24-25	3803-3805	of	abstract[176]	new[176]	_	_
24-26	3806-3809	the	abstract[176]|person[177]|person[178]	new[176]|new[177]|giv[178]	coref|coref|coref|coref	26-9[192_177]|26-9[193_178]|26-9[192_177]|26-9[193_178]
24-27	3810-3818	patients	abstract[176]|person[177]|person[178]	new[176]|new[177]|giv[178]	_	_
24-28	3819-3822	and	abstract[176]|person[178]	new[176]|giv[178]	_	_
24-29	3823-3835	side-effects	abstract[176]|person[178]|abstract[179]	new[176]|giv[178]|new[179]	_	_
24-30	3836-3838	of	abstract[176]|person[178]|abstract[179]	new[176]|giv[178]|new[179]	_	_
24-31	3839-3842	the	abstract[176]|person[178]|abstract[179]|substance[180]	new[176]|giv[178]|new[179]|new[180]	_	_
24-32	3843-3849	second	abstract[176]|person[178]|abstract[179]|substance[180]	new[176]|giv[178]|new[179]|new[180]	_	_
24-33	3850-3875	generation-antipsychotics	abstract[176]|person[178]|abstract[179]|substance[180]	new[176]|giv[178]|new[179]|new[180]	_	_
24-34	3876-3877	.	_	_	_	_

#Text=On the other hand , THMs such as As and Pb were found to be associated with metabolic diseases , suggesting a role of abnormal metabolisms in linking THMs and schizophrenia .
25-1	3878-3880	On	_	_	_	_
25-2	3881-3884	the	_	_	_	_
25-3	3885-3890	other	_	_	_	_
25-4	3891-3895	hand	_	_	_	_
25-5	3896-3897	,	_	_	_	_
25-6	3898-3902	THMs	abstract	giv	coref	25-29[187_0]
25-7	3903-3907	such	_	_	_	_
25-8	3908-3910	as	_	_	_	_
25-9	3911-3913	As	_	_	_	_
25-10	3914-3917	and	_	_	_	_
25-11	3918-3920	Pb	substance	giv	coref	26-36
25-12	3921-3925	were	_	_	_	_
25-13	3926-3931	found	_	_	_	_
25-14	3932-3934	to	_	_	_	_
25-15	3935-3937	be	_	_	_	_
25-16	3938-3948	associated	_	_	_	_
25-17	3949-3953	with	_	_	_	_
25-18	3954-3963	metabolic	object|abstract[184]	giv|giv[184]	coref|coref	27-9|27-9
25-19	3964-3972	diseases	abstract[184]	giv[184]	_	_
25-20	3973-3974	,	_	_	_	_
25-21	3975-3985	suggesting	_	_	_	_
25-22	3986-3987	a	abstract[185]	giv[185]	_	_
25-23	3988-3992	role	abstract[185]	giv[185]	_	_
25-24	3993-3995	of	abstract[185]	giv[185]	_	_
25-25	3996-4004	abnormal	abstract[185]|abstract[186]	giv[185]|new[186]	coref	27-16[210_186]
25-26	4005-4016	metabolisms	abstract[185]|abstract[186]	giv[185]|new[186]	_	_
25-27	4017-4019	in	_	_	_	_
25-28	4020-4027	linking	_	_	_	_
25-29	4028-4032	THMs	abstract[187]	giv[187]	coref	26-25[198_187]
25-30	4033-4036	and	abstract[187]	giv[187]	_	_
25-31	4037-4050	schizophrenia	abstract[187]|abstract	giv[187]|giv	coref	26-12
25-32	4051-4052	.	_	_	_	_

#Text=Therefore , we performed a case-control study with first-episode and drug-naïve schizophrenia patients and healthy controls to identify the association between serum concentrations of the 4 THMs ( i. e. , Cr , Cd , Pb and As , selected as commonly surveyed heavy metals in schizophrenia studies ) and the risk of schizophrenia .
26-1	4053-4062	Therefore	_	_	_	_
26-2	4063-4064	,	_	_	_	_
26-3	4065-4067	we	person	acc	_	_
26-4	4068-4077	performed	_	_	_	_
26-5	4078-4079	a	abstract[190]	giv[190]	_	_
26-6	4080-4092	case-control	abstract[190]	giv[190]	_	_
26-7	4093-4098	study	abstract[190]	giv[190]	_	_
26-8	4099-4103	with	abstract[190]	giv[190]	_	_
26-9	4104-4117	first-episode	abstract[190]|person[192]|person[193]	giv[190]|giv[192]|giv[193]	_	_
26-10	4118-4121	and	abstract[190]|person[192]|person[193]	giv[190]|giv[192]|giv[193]	_	_
26-11	4122-4132	drug-naïve	abstract[190]|person[192]|person[193]	giv[190]|giv[192]|giv[193]	_	_
26-12	4133-4146	schizophrenia	abstract[190]|abstract|person[192]|person[193]	giv[190]|giv|giv[192]|giv[193]	coref	26-47
26-13	4147-4155	patients	abstract[190]|person[192]|person[193]	giv[190]|giv[192]|giv[193]	_	_
26-14	4156-4159	and	abstract[190]|person[193]	giv[190]|giv[193]	_	_
26-15	4160-4167	healthy	abstract[190]|person[193]|person[194]	giv[190]|giv[193]|giv[194]	_	_
26-16	4168-4176	controls	abstract[190]|person[193]|person[194]	giv[190]|giv[193]|giv[194]	_	_
26-17	4177-4179	to	_	_	_	_
26-18	4180-4188	identify	_	_	_	_
26-19	4189-4192	the	abstract[195]	giv[195]	coref	28-9[214_195]
26-20	4193-4204	association	abstract[195]	giv[195]	_	_
26-21	4205-4212	between	abstract[195]	giv[195]	_	_
26-22	4213-4218	serum	abstract[195]|substance|abstract[197]	giv[195]|giv|giv[197]	_	_
26-23	4219-4233	concentrations	abstract[195]|abstract[197]	giv[195]|giv[197]	_	_
26-24	4234-4236	of	abstract[195]|abstract[197]	giv[195]|giv[197]	_	_
26-25	4237-4240	the	abstract[195]|abstract[197]|abstract[198]	giv[195]|giv[197]|giv[198]	appos	26-29[199_198]
26-26	4241-4242	4	abstract[195]|abstract[197]|abstract[198]	giv[195]|giv[197]|giv[198]	_	_
26-27	4243-4247	THMs	abstract[195]|abstract[197]|abstract[198]	giv[195]|giv[197]|giv[198]	_	_
26-28	4248-4249	(	_	_	_	_
26-29	4250-4252	i.	abstract[199]	giv[199]	coref	26-44[201_199]
26-30	4253-4255	e.	abstract[199]	giv[199]	_	_
26-31	4256-4257	,	abstract[199]	giv[199]	_	_
26-32	4258-4260	Cr	abstract[199]	giv[199]	_	_
26-33	4261-4262	,	abstract[199]	giv[199]	_	_
26-34	4263-4265	Cd	abstract[199]	giv[199]	_	_
26-35	4266-4267	,	abstract[199]	giv[199]	_	_
26-36	4268-4270	Pb	abstract[199]|abstract	giv[199]|giv	_	_
26-37	4271-4274	and	_	_	_	_
26-38	4275-4277	As	_	_	_	_
26-39	4278-4279	,	_	_	_	_
26-40	4280-4288	selected	_	_	_	_
26-41	4289-4291	as	_	_	_	_
26-42	4292-4300	commonly	_	_	_	_
26-43	4301-4309	surveyed	_	_	_	_
26-44	4310-4315	heavy	substance[201]	giv[201]	coref	27-4[207_201]
26-45	4316-4322	metals	substance[201]	giv[201]	_	_
26-46	4323-4325	in	substance[201]	giv[201]	_	_
26-47	4326-4339	schizophrenia	substance[201]|abstract|abstract[203]	giv[201]|giv|giv[203]	coref|coref	26-54|26-54
26-48	4340-4347	studies	substance[201]|abstract[203]	giv[201]|giv[203]	_	_
26-49	4348-4349	)	substance[201]	giv[201]	_	_
26-50	4350-4353	and	substance[201]	giv[201]	_	_
26-51	4354-4357	the	substance[201]|abstract[204]	giv[201]|giv[204]	coref	28-17[216_204]
26-52	4358-4362	risk	substance[201]|abstract[204]	giv[201]|giv[204]	_	_
26-53	4363-4365	of	substance[201]|abstract[204]	giv[201]|giv[204]	_	_
26-54	4366-4379	schizophrenia	substance[201]|abstract[204]|abstract	giv[201]|giv[204]|giv	coref	27-24
26-55	4380-4381	.	_	_	_	_

#Text=The correlations between the 4 THMs and multiple metabolic biomarkers were also tested to explore the potential metabolisms associated between these THMs and schizophrenia .
27-1	4382-4385	The	abstract[206]	new[206]	_	_
27-2	4386-4398	correlations	abstract[206]	new[206]	_	_
27-3	4399-4406	between	abstract[206]	new[206]	_	_
27-4	4407-4410	the	abstract[206]|abstract[207]	new[206]|giv[207]	coref	27-21[211_207]
27-5	4411-4412	4	abstract[206]|abstract[207]	new[206]|giv[207]	_	_
27-6	4413-4417	THMs	abstract[206]|abstract[207]	new[206]|giv[207]	_	_
27-7	4418-4421	and	abstract[206]|abstract[207]	new[206]|giv[207]	_	_
27-8	4422-4430	multiple	abstract[206]|abstract[207]|abstract[209]	new[206]|giv[207]|new[209]	_	_
27-9	4431-4440	metabolic	abstract[206]|abstract[207]|person|abstract[209]	new[206]|giv[207]|giv|new[209]	_	_
27-10	4441-4451	biomarkers	abstract[206]|abstract[207]|abstract[209]	new[206]|giv[207]|new[209]	_	_
27-11	4452-4456	were	_	_	_	_
27-12	4457-4461	also	_	_	_	_
27-13	4462-4468	tested	_	_	_	_
27-14	4469-4471	to	_	_	_	_
27-15	4472-4479	explore	_	_	_	_
27-16	4480-4483	the	abstract[210]	giv[210]	_	_
27-17	4484-4493	potential	abstract[210]	giv[210]	_	_
27-18	4494-4505	metabolisms	abstract[210]	giv[210]	_	_
27-19	4506-4516	associated	_	_	_	_
27-20	4517-4524	between	_	_	_	_
27-21	4525-4530	these	abstract[211]	giv[211]	coref	28-12[215_211]
27-22	4531-4535	THMs	abstract[211]	giv[211]	_	_
27-23	4536-4539	and	abstract[211]	giv[211]	_	_
27-24	4540-4553	schizophrenia	abstract[211]|abstract	giv[211]|giv	coref	28-20
27-25	4554-4555	.	_	_	_	_

#Text=Furthermore , meta-analysis was conducted to comprehensively summarize the association between the 4 individual THMs and the risk of schizophrenia .
28-1	4556-4567	Furthermore	_	_	_	_
28-2	4568-4569	,	_	_	_	_
28-3	4570-4583	meta-analysis	abstract	new	_	_
28-4	4584-4587	was	_	_	_	_
28-5	4588-4597	conducted	_	_	_	_
28-6	4598-4600	to	_	_	_	_
28-7	4601-4616	comprehensively	_	_	_	_
28-8	4617-4626	summarize	_	_	_	_
28-9	4627-4630	the	abstract[214]	giv[214]	_	_
28-10	4631-4642	association	abstract[214]	giv[214]	_	_
28-11	4643-4650	between	abstract[214]	giv[214]	_	_
28-12	4651-4654	the	abstract[214]|abstract[215]	giv[214]|giv[215]	_	_
28-13	4655-4656	4	abstract[214]|abstract[215]	giv[214]|giv[215]	_	_
28-14	4657-4667	individual	abstract[214]|abstract[215]	giv[214]|giv[215]	_	_
28-15	4668-4672	THMs	abstract[214]|abstract[215]	giv[214]|giv[215]	_	_
28-16	4673-4676	and	abstract[214]|abstract[215]	giv[214]|giv[215]	_	_
28-17	4677-4680	the	abstract[214]|abstract[215]|abstract[216]	giv[214]|giv[215]|giv[216]	_	_
28-18	4681-4685	risk	abstract[214]|abstract[215]|abstract[216]	giv[214]|giv[215]|giv[216]	_	_
28-19	4686-4688	of	abstract[214]|abstract[215]|abstract[216]	giv[214]|giv[215]|giv[216]	_	_
28-20	4689-4702	schizophrenia	abstract[214]|abstract[215]|abstract[216]|abstract	giv[214]|giv[215]|giv[216]|giv	_	_
28-21	4703-4704	.	_	_	_	_
